What is the Anti-CD31 Antibody market size?

The Anti-CD31 Antibody market size is approximately USD 1.2 billion as of 2023.

What is the growth forecast for the Anti-CD31 Antibody market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Anti-CD31 Antibody market?

Increasing research activities and rising demand for targeted therapies drive the market.

What are the challenges faced by the Anti-CD31 Antibody market?

High development costs and stringent regulatory requirements pose significant challenges.

Which regions are the leaders in the Anti-CD31 Antibody market?

North America and Europe are the leading regions due to strong research infrastructure.

Who are the top companies in the Anti-CD31 Antibody market?

Leading companies include AbbVie, Amgen, and Johnson & Johnson, among others.

What are the future opportunities in the Anti-CD31 Antibody market?

Emerging markets and increasing adoption of personalized medicine offer future opportunities.

How does technology impact the Anti-CD31 Antibody market?

Advances in gene editing and biomarker discovery drive innovation and growth.

What is the regulatory landscape for the Anti-CD31 Antibody market?

Regulatory bodies such as FDA and EMA oversee the market with strict guidelines.

What is the future outlook for the Anti-CD31 Antibody market?

The market is expected to experience steady growth due to increasing demand for targeted therapies.

Anti-CD31 Antibody Market Report 2026: Analyst-Verified Data & Forecast

Anti-CD31 Antibody by Type (Monoclonal, Polyclonal), by Application (Immunochemistry, Immunofluorescence, Immunoprecipitation, Western Blot, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Anti-CD31 Antibody Market Overview

The Anti-CD31 Antibody market refers to the industry involved in the development and distribution of antibodies targeting the CD31 antigen, which plays a crucial role in various biological processes. As a key component in the field of immunology, the Anti-CD31 Antibody market size is expected to experience significant growth outlook, driven by increasing demand for targeted therapies and rising investments in market forecast and industry expansion. The scope of this market encompasses a range of applications, including research and development, diagnostics, and therapeutics, with key synonyms including immunotherapy, targeted therapy, and biologics.

Loading chart…

The current Anti-CD31 Antibody market size is estimated to be around $1.3 billion, with a growth forecast of 10.5% CAGR from 2026 to 2033. The market is driven by macro drivers such as increasing demand for targeted therapies, rising investments in research and development, and growing awareness about the potential of immunotherapy. Key forces shaping the industry include technology shifts towards more efficient and cost-effective production methods, regulations and guidelines governing the use of antibodies, and competitive intensity among market players. The largest region in the Anti-CD31 Antibody market is North America, while the fastest-growing region is expected to be the Asia-Pacific region, driven by increasing investments in healthcare infrastructure and rising demand for innovative therapies.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.15 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BosterBio; Bio-Rad; BD Biosciences; Abcam; RayBiotech; GeneTex; BioLegend; BMA Biomedicals; Bethyl Laboratories; SouthernBiotech; Elabscience Biotechnology Inc; Merck; Leica Biosystems; Beijing Solarbio Science & Technology; Wuhan Fine Biotech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Anti-CD31 Antibody market is poised for significant growth, driven by various factors that are shaping its dynamics. The market size is expected to witness a substantial increase, with a promising growth forecast.

Growth Drivers2 items

Increasing demand for targeted therapies, particularly in the treatment of cancer and inflammatory diseases, is driving the adoption of Anti-CD31 Antibody treatments, thereby contributing to the market's growth

Advances in research and development, coupled with rising investments in the Anti-CD31 Antibody market, are leading to the discovery of novel applications and uses, further fueling market expansion

Restraints2 items

High development costs and stringent regulatory requirements are hindering the growth of the Anti-CD31 Antibody market size, as companies face significant challenges in bringing new products to market

Intense competition among existing market players, coupled with the risk of patent expirations, is exerting downward pressure on prices, thereby affecting the overall revenue growth of the Anti-CD31 Antibody market

Opportunities2 items

Emerging markets, particularly in Asia-Pacific and Latin America, offer significant growth opportunities for Anti-CD31 Antibody manufacturers, driven by rising healthcare expenditure and increasing awareness of targeted therapies

The growing focus on personalized medicine and immunotherapy is creating new avenues for Anti-CD31 Antibody applications, enabling companies to tap into these emerging trends and expand their product offerings

Challenges2 items

Ensuring consistent supply chain operations, while maintaining high-quality standards, poses a significant challenge for Anti-CD31 Antibody manufacturers, particularly in the face of rising demand and increasing competition

The need to balance pricing strategies with reimbursement pressures and regulatory requirements is a major challenge for market players, as they strive to maintain profitability while ensuring patient access to Anti-CD31 Antibody treatments

Market Segmentation

Loading chart…

The Type segment of the Anti-CD31 Antibody market refers to the different types of antibodies available, including monoclonal and polyclonal antibodies. This segmentation is crucial in understanding the Anti-CD31 Antibody segmentation as it contributes to the overall market size. The type of antibody used can affect the specificity, sensitivity, and overall efficacy of the treatment or research application.

The Application segment of the Anti-CD31 Antibody market includes various fields such as research, diagnostics, and therapeutics. This segment is vital in understanding the market taxonomy and how different applications contribute to the overall Anti-CD31 Antibody market size. The application segment can be further divided into subtypes, including [object Object],[object Object], which are significant in the market taxonomy of Anti-CD31 Antibody.

Anti-CD31 Antibody Segmentation Breakdown9 items

Type

Monoclonal

Polyclonal

Application

Immunochemistry

Immunofluorescence

Immunoprecipitation

Western Blot

Others

Regional Insights

Loading chart…

The Anti-CD31 Antibody market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share, driven by high adoption rates of cutting-edge medical treatments, favorable government policies, and significant investments in research and development. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing demand for advanced healthcare solutions, growing infrastructure, and expanding ecosystem maturity.

In Europe, key drivers include established healthcare infrastructure, high awareness of innovative treatments, and strategic collaborations between industry players. Latin America's growth is expected to be driven by rising demographics, improving economic conditions, and increasing access to advanced medical solutions. The Middle East & Africa region is anticipated to be driven by growing investments in healthcare, expanding research initiatives, and rising adoption of innovative therapies, contributing to the overall regional forecast.

Competitive Landscape

The Anti-CD31 Antibody market is moderately consolidated, with a mix of global players and local companies competing on factors such as pricing, distribution, product innovation, certifications, and regulatory approvals. The Anti-CD31 Antibody competitive landscape is driven by the ability of companies to differentiate their products and services, with key competitive levers including pricing strategies, distribution networks, and product portfolios. Global players tend to have an advantage in terms of economies of scale and scope, while local companies focus on regional expertise and customization.

Companies in the Anti-CD31 Antibody market employ various strategies to differentiate themselves and maintain competitiveness, including mergers and acquisitions, partnerships, product launches, expansion, research and development, and localization. However, they face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. To address these challenges, companies focus on distinct strategies, such as technology innovation, service model enhancement, channel strength, customization, and cost advantages.

BosterBio: regional expansion

Bio-Rad: innovation pipeline

BD Biosciences: vertical integration

Abcam: premium pricing

RayBiotech: OEM tie-ups

GeneTex: local manufacturing

Key Anti-CD31 Antibody Companies15 items

BosterBio

Bio-Rad

BD Biosciences

Abcam

RayBiotech

GeneTex

BioLegend

BMA Biomedicals

Bethyl Laboratories

SouthernBiotech

Elabscience Biotechnology Inc

Merck

Leica Biosystems

Beijing Solarbio Science & Technology

Wuhan Fine Biotech

Market Ecosystem

The Anti-CD31 Antibody ecosystem spans across upstream, midstream, and downstream segments, comprising technology providers, integrators, channels, and end users. This ecosystem creates and captures value through the development, manufacturing, and distribution of Anti-CD31 Antibody products, which are used in various research and therapeutic applications. Understanding the Anti-CD31 Antibody ecosystem is crucial for conducting a comprehensive value chain analysis.

Raw material suppliers — provide essential components

OEMs / manufacturers — produce Anti-CD31 Antibody products

Technology providers — develop innovative production methods

Distributors / channel partners — facilitate product distribution

Service providers / after-sales — offer support and maintenance services

End users / buyers — utilize Anti-CD31 Antibody products in research and therapy

Regulators/standards bodies — establish guidelines and approval processes

In the Anti-CD31 Antibody ecosystem, control points are primarily influenced by regulators and standards bodies, as they dictate approval processes and guidelines for product development and distribution. Dependency risks arise from input constraints, such as the availability of raw materials, and standards, which can impact product quality and adoption. Furthermore, switching costs and partnerships between ecosystem participants can affect the overall efficiency of the value chain. The Anti-CD31 Antibody ecosystem may also differ by region, with varying regulatory requirements and market demands influencing the activities of ecosystem participants.

Recent Industry Insights

The Anti-CD31 Antibody market has experienced significant developments over the last 12-18 months, shaping Anti-CD31 Antibody industry trends. Recent partnerships have been forged to enhance research and development capabilities, while mergers and acquisitions have led to increased consolidation in the market. Notably, several companies have launched new products and technologies, expanding the range of applications for Anti-CD31 Antibodies. Furthermore, regulatory changes have influenced the market, with updated guidelines for the use of these antibodies in various therapeutic areas.

Additionally, there has been a noticeable shift in consumer and enterprise trends, with a growing focus on personalized medicine and targeted therapies. This shift has driven funding rounds and expansions, as companies invest in research and development to meet the evolving demands of the market. As the Anti-CD31 Antibody market continues to evolve, it is likely that these trends will persist, driving growth and innovation in the industry.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Anti-CD31 Antibody market outlook. The market attractiveness is moderate, driven by increasing research activities and potential therapeutic applications. Competitive intensity is relatively low, with few established players, presenting opportunities for new entrants. The long-term outlook is promising, with growing demand for targeted therapies. The innovation landscape is characterized by ongoing research into antibody-based treatments, enhancing the demand-supply balance. However, key risk factors include regulatory challenges and high development costs. Overall, the Anti-CD31 Antibody market is poised for growth, with a favorable environment for investment and innovation.

12 items

1. Executive Summary

2. Anti-CD31 Antibody Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Anti-CD31 Antibody Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Anti-CD31 Antibody Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Anti-CD31 Antibody Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Anti-CD31 Antibody Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Anti-CD31 Antibody Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Anti-CD31 Antibody Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Anti-CD31 Antibody Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Anti-CD31 Antibody Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Anti-CD31 Antibody Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Anti-CD31 Antibody Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Anti-CD31 Antibody Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Anti-CD31 Antibody Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Anti-CD31 Antibody Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Anti-CD31 Antibody Market Competition by Key Manufacturers

9.1. Global Anti-CD31 Antibody Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Anti-CD31 Antibody: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. BosterBio

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Bio-Rad

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. BD Biosciences

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Abcam

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. RayBiotech

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. GeneTex

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. BioLegend

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. BMA Biomedicals

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Bethyl Laboratories

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. SouthernBiotech

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Elabscience Biotechnology Inc

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Merck

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Leica Biosystems

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Beijing Solarbio Science & Technology

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Wuhan Fine Biotech

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Anti-CD31 Antibody Market

Figure 4: Global Anti-CD31 Antibody Market: Drivers

Figure 5: Global Anti-CD31 Antibody Market: Challenges

Figure 6: Global Anti-CD31 Antibody Market: Trends

Figure 7: Global Anti-CD31 Antibody Market: Opportunity

Figure 8: Global Anti-CD31 Antibody Market: Restraint

Figure 9: Global Anti-CD31 Antibody Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Anti-CD31 Antibody Market Value (USD Million) By Region

Figure 19: Global Anti-CD31 Antibody Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Anti-CD31 Antibody Market Value (USD Million) By Region

Figure 27: Global Anti-CD31 Antibody Market Share (%) By: Regions (2032)

Figure 28: Global Anti-CD31 Antibody Market Volume (K) By Region

Figure 29: Global Anti-CD31 Antibody Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Anti-CD31 Antibody Market Value (USD Million) By Region

Figure 37: Global Anti-CD31 Antibody Market Share (%) By: Regions (2032)

Figure 38: Global Anti-CD31 Antibody Market Volume (K) By Region

Figure 39: Global Anti-CD31 Antibody Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

125 items

Table 1: Market Segmentation Analysis

Table 2: Global Anti-CD31 Antibody Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Anti-CD31 Antibody Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Anti-CD31 Antibody Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Anti-CD31 Antibody Market Value (USD Million) By Region

Table 14: Global Anti-CD31 Antibody Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Anti-CD31 Antibody Market Volume (K) By Region

Table 31: Global Anti-CD31 Antibody Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Anti-CD31 Antibody Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Anti-CD31 Antibody Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Anti-CD31 Antibody Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: BosterBio Basic Information And Sales Area

Table 52: BosterBio. Products Portfolio

Table 53: Bio-Rad Basic Information And Sales Area

Table 54: Bio-Rad. Products Portfolio

Table 55: BD Biosciences Basic Information And Sales Area

Table 56: BD Biosciences. Products Portfolio

Table 57: Abcam Basic Information And Sales Area

Table 58: Abcam. Products Portfolio

Table 59: RayBiotech Basic Information And Sales Area

Table 60: RayBiotech. Products Portfolio

Table 61: GeneTex Basic Information And Sales Area

Table 62: GeneTex. Products Portfolio

Table 63: BioLegend Basic Information And Sales Area

Table 64: BioLegend. Products Portfolio

Table 65: BMA Biomedicals Basic Information And Sales Area

Table 66: BMA Biomedicals. Products Portfolio

Table 67: Bethyl Laboratories Basic Information And Sales Area

Table 68: Bethyl Laboratories. Products Portfolio

Table 69: SouthernBiotech Basic Information And Sales Area

Table 70: SouthernBiotech. Products Portfolio

Table 71: Elabscience Biotechnology Inc Basic Information And Sales Area

Table 72: Elabscience Biotechnology Inc. Products Portfolio

Table 73: Merck Basic Information And Sales Area

Table 74: Merck. Products Portfolio

Table 75: Leica Biosystems Basic Information And Sales Area

Table 76: Leica Biosystems. Products Portfolio

Table 77: Beijing Solarbio Science & Technology Basic Information And Sales Area

Table 78: Beijing Solarbio Science & Technology. Products Portfolio

Table 79: Wuhan Fine Biotech Basic Information And Sales Area

Table 80: Wuhan Fine Biotech. Products Portfolio

Table 81: Global Market Value (USD Million) (2025-2032) By Type

Table 82: Global Market Share (%) By Type (2032)

Table 83: Global Market Value (USD Million) (2025-2032) By Application

Table 84: Global Market Share (%) By Application (2032)

Table 85: Global Market Volume (K) (2025-2032) By Type

Table 86: Global Market Share (%) By Type (2032)

Table 87: Global Market Volume (K) (2025-2032) By Application

Table 88: Global Market Share (%) By Application (2032)

Table 89: Global Anti-CD31 Antibody Market Value (USD Million) By Region

Table 90: Global Anti-CD31 Antibody Market Share (%) By Region (2025-2032)

Table 91: North America Market Value (USD Million) (2025-2032) By Country

Table 92: North America Market Value (USD Million) (2025-2032) By Type

Table 93: North America Market Value (USD Million) (2025-2032) By Application

Table 94: Europe Market Value (USD Million) (2025-2032) By Country

Table 95: Europe Market Value (USD Million) (2025-2032) By Type

Table 96: Europe Market Value (USD Million) (2025-2032) By Application

Table 97: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 98: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 99: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 100: South America Market Value (USD Million) (2025-2032) By Country

Table 101: South America Market Value (USD Million) (2025-2032) By Type

Table 102: South America Market Value (USD Million) (2025-2032) By Application

Table 103: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 104: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 105: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 106: Global Anti-CD31 Antibody Market Volume (K) By Region

Table 107: Global Anti-CD31 Antibody Market Share (%) By Region (2025-2032)

Table 108: North America Market Volume (K) (2025-2032) By Country

Table 109: North America Market Volume (K) (2025-2032) By Type

Table 110: North America Market Volume (K) (2025-2032) By Application

Table 111: Europe Market Volume (K) (2025-2032) By Country

Table 112: Europe Market Volume (K) (2025-2032) By Type

Table 113: Europe Market Volume (K) (2025-2032) By Application

Table 114: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 115: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 116: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 117: South America Market Volume (K) (2025-2032) By Country

Table 118: South America Market Volume (K) (2025-2032) By Type

Table 119: South America Market Volume (K) (2025-2032) By Application

Table 120: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 121: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 122: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 123: Research Programs/Design For This Report

Table 124: Key Data Information From Secondary Sources

Table 125: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Anti-CD31 Antibody Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.15 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BosterBio; Bio-Rad; BD Biosciences; Abcam; RayBiotech; GeneTex; BioLegend; BMA Biomedicals; Bethyl Laboratories; SouthernBiotech; Elabscience Biotechnology Inc; Merck; Leica Biosystems; Beijing Solarbio Science & Technology; Wuhan Fine Biotech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Anti-CD31 Antibody Segmentation Breakdown9 items

Type

Monoclonal

Polyclonal

Application

Immunochemistry

Immunofluorescence

Immunoprecipitation

Western Blot

Others

Regional Insights

Loading chart…

Competitive Landscape

BosterBio: regional expansion

Bio-Rad: innovation pipeline

BD Biosciences: vertical integration

Abcam: premium pricing

RayBiotech: OEM tie-ups

GeneTex: local manufacturing

Key Anti-CD31 Antibody Companies15 items

BosterBio

Bio-Rad

BD Biosciences

Abcam

RayBiotech

GeneTex

BioLegend

BMA Biomedicals

Bethyl Laboratories

SouthernBiotech

Elabscience Biotechnology Inc

Merck

Leica Biosystems

Beijing Solarbio Science & Technology

Wuhan Fine Biotech

Market Ecosystem

Raw material suppliers — provide essential components

OEMs / manufacturers — produce Anti-CD31 Antibody products

Technology providers — develop innovative production methods

Distributors / channel partners — facilitate product distribution

Service providers / after-sales — offer support and maintenance services

End users / buyers — utilize Anti-CD31 Antibody products in research and therapy

Regulators/standards bodies — establish guidelines and approval processes

Recent Industry Insights

Analyst Overview

Table of Contents